Clinical Trial Update: A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders [Phase 2]

View source ↗

Summary

Phase 2 study comparing antiplatelet effects of ticagrelor versus clopidogrel in responders and non-responders with stable coronary artery disease, with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stable Coronary Artery Disease

Drugs mentioned

• CLOPIDOGREL (CLOPIDOGREL)
• TICAGRELOR (ticagrelor)

Snippet

Sponsor: AstraZeneca | Conditions: Stable Coronary Artery Disease | Phase 2 | Status: COMPLETED | Results posted: 2011-10-04